AK MEDICAL1789.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, AK MEDICAL (1789.HK) trades at a P/E of 11.70x, P/B of 1.58x, P/S of 2.83x, and a dividend yield of 2.62%.
Longitudinal percentile comparison: P/E sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/B sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 38th percentile within its industry and the 53rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 7.98%, ranking at the 100th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 0.2 points, pointing to a consistent valuation read across both metrics. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Breaking down the total shareholder yield: 2.62% comes from cash dividends, with an implied ~5.36% from buybacks — a fairly balanced mix of both channels. AK MEDICAL operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 1789 · SEHK: 1789 · 1789
Want the full picture on whether AK MEDICAL (1789.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 11.70 | ||||||
| P/B (MRQ) | 1.58 | ||||||
| P/S (TTM) | 2.83 | ||||||
| Dividend Yield | 2.62% | ||||||
| Buyback + Div Yield | 7.98% |